Adria Carbo
Vice President & Head of Business Development Artiva Biotherapeutics
Seminars
Wednesday 2nd December 2026
Audience Discussion: Deal-Making & Acquisition Drivers in the Next Wave of Cell Therapy
4:00 pm
- Evaluating which cell therapy modalities and platforms are attracting investment and acquisition interest
- Assessing competitive positioning as multiple programs advance toward pivotal trials and regulatory submissions
- Understanding investor perspectives on autologous versus allogeneic versus in vivo approaches for long-term market viability
Thursday 3rd December 2026
Audience Discussion: Modality Debate – Autologous vs Allogeneic vs In Vivo
9:00 am
- Debating which platform will dominate the autoimmune cell therapy landscape long-term
- Evaluating trade-offs between manufacturing control, patient convenience, safety, and efficacy
- Assessing whether ex vivo autologous approaches represent a transitional technology or enduring solution
